Extend Protection From CV Mortality or Nonfatal MI Across the Risk Spectrum of Your Stable CAD Patients1-3
ACEON® 8 mg:CV event reduction (CV mortality or nonfatal MI) in stable CAD patients, even in patients ≤ 55 years of age
EUROPA: 20% relative risk reduction of the combined primary endpoint in 12,218 stable CAD patients
CV mortality, nonfatal MI, or cardiac arrest [perindopril 488 (8.0%) vs placebo 603 (9.9%)] (P=0.0003) 1,2
Approximately one-third of patients in the study were aged 55 years or less1,2
The benefit was consistent across all predefined subgroups regardless of gender, age, or underlying disease1,2
ACEON®provides benefits in patients receiving contemporary CV protective therapies1,2
ACEON®provides continuous 24-hour BP control that is clinically proven with convenient dosing3,4
Indicated in Patients With Stable Coronary Artery Disease 2
ACEON® is indicated in patients with stable coronary artery disease to reduce the risk of cardiovascular mortality or nonfatal myocardial infarction. ACEON® can be used with conventional treatment for management of coronary artery disease, such as antiplatelet, antihypertensive, or lipid-lowering therapy.
ACEON® is also indicated for the treatment of patients with essential hypertension.
USE IN PREGNANCY 2
When used in pregnancy during the second and third trimesters, ACE inhibitors can cause injury and even death to the developing fetus. When pregnancy is detected, ACEON® should be discontinued as soon as possible. See WARNINGS: Fetal/Neonatal Morbidity and Mortality.
